Results 51 to 60 of about 23,525 (109)

Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study. [PDF]

BMC Infect Dis
Fujioka H, Matsui H, Homma Y, Nagai T, Otsuki A, Ito H, Ohmura S, Miyamoto T, Shichi D, Tomohisa W, Otsuka Y, Nakashima K.   +11 more
europepmc   +1 more source

Pneumocystis pneumonia in French intensive care units in 2013-2019: mortality and immunocompromised conditions. [PDF]

Ann Intensive Care
Kamel T, Boulain T.
europepmc   +1 more source

Pneumocystis pneumonia

, 2013
openaire   +2 more sources

["Pneumocystis" pneumonia].

Jornal de pediatria, 1998
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pneumocystis Pneumonia

Seminars in Respiratory and Critical Care Medicine, 2011
Pneumocystis (carinii) jiroveci pneumonia can occur in immunocompromised individuals, especially hematopoietic stem and solid organ transplant recipients and those receiving immunosuppressive agents, and is the most common opportunistic infection in persons with advanced human immunodeficiency virus (HIV) infection. The Pneumocystis genus was initially
Shelley A, Gilroy, Nicholas J, Bennett
exaly   +3 more sources

Pneumocystis Pneumonia

Pediatric Clinics of North America, 1958
Pneumocystis carinii pneumonia or interstitial plasma-cell pneumonia is a common infection in Europe, where it occurs endemically or in small institutional epidemics. It affects chiefly premature or otherwise debilitated infants with a peak incidence at the age from 6 weeks to 4 months, but the disease has also been encountered in three adults.1In this
R M, HOWARD, W H, SHELDON
openaire   +4 more sources